Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1775)	4/23/2007 12:43:06 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

It seems that OSIP isn't worried about Erbitux possible competition with Terciva for pancreatic Ca.<g> The stock is acting well & trying to get off from the DT coming from its Apr 2004 H at 98.70, but probably will be better to wait until it trades above its Oct H at 43.17 <g> bigcharts.marketwatch.com bigcharts.marketwatch.com OSIP Is expected to close on the black for the first time this Yr. around $1/shr & for 2008 EE are around $1.40, but if Erbitux results for pancreatic Ca are better than the slim margin of Terciva over placebo, the EE could be much different.<g> Bernard